NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Last Close
May 13 04:00PM ET
0.7025
Dollar change
+0.0025
Percentage change
0.36
%
IndexRUT P/E- EPS (ttm)-0.19 Insider Own1.80% Shs Outstand292.03M Perf Week-1.78%
Market Cap205.15M Forward P/E- EPS next Y-0.24 Insider Trans0.67% Shs Float286.77M Perf Month1.75%
Income-52.49M PEG- EPS next Q-0.06 Inst Own24.37% Short Float23.79% Perf Quarter4.52%
Sales4.52M P/S45.39 EPS this Y-25.00% Inst Trans-12.59% Short Ratio18.26 Perf Half Y-34.95%
Book/sh0.05 P/B12.89 EPS next Y4.00% ROA-98.89% Short Interest68.23M Perf Year-57.93%
Cash/sh0.13 P/C5.43 EPS next 5Y- ROE-248.97% 52W Range0.51 - 2.06 Perf YTD-12.73%
Dividend Est.- P/FCF- EPS past 5Y32.82% ROI-111.69% 52W High-65.90% Beta4.20
Dividend TTM- Quick Ratio2.60 Sales past 5Y1.96% Gross Margin40.34% 52W Low36.41% ATR (14)0.06
Dividend Ex-Date- Current Ratio2.60 EPS Y/Y TTM22.29% Oper. Margin-1261.43% RSI (14)50.88 Volatility8.27% 7.18%
Employees95 Debt/Eq2.00 Sales Y/Y TTM86.63% Profit Margin-1160.86% Recom1.00 Target Price6.50
Option/ShortYes / Yes LT Debt/Eq1.95 EPS Q/Q-13.36% Payout- Rel Volume0.84 Prev Close0.70
Sales Surprise- EPS Surprise13.04% Sales Q/Q46.06% EarningsMay 09 BMO Avg Volume3.74M Price0.70
SMA20-0.74% SMA506.28% SMA200-20.81% Trades Volume3,126,481 Change0.36%
Date Action Analyst Rating Change Price Target Change
Oct-15-24Initiated Maxim Group Buy $4
Mar-01-23Upgrade Chardan Capital Markets Neutral → Buy $3.50
Aug-23-22Initiated Mizuho Buy $5
Jun-15-22Resumed ROTH Capital Buy $8
Jun-02-22Initiated Cantor Fitzgerald Overweight $4.50
Jul-26-21Initiated Noble Capital Markets Outperform
Jun-11-21Downgrade ROTH Capital Buy → Neutral $10 → $6
May-07-21Downgrade Cantor Fitzgerald Overweight → Neutral
Feb-09-21Downgrade Chardan Capital Markets Buy → Neutral $0.70 → $13
Feb-04-21Upgrade H.C. Wainwright Neutral → Buy $4.50
May-10-25 03:04AM
May-09-25 08:07AM
08:01AM
May-02-25 08:00AM
Apr-29-25 07:30AM
10:01AM Loading…
Apr-16-25 10:01AM
Apr-08-25 08:02AM
Mar-26-25 08:50AM
Mar-19-25 06:18AM
Mar-18-25 08:02AM
Mar-06-25 02:07AM
Mar-05-25 11:48PM
01:15PM
07:21AM
07:02AM
09:00AM Loading…
Mar-03-25 09:00AM
08:26AM
Feb-27-25 08:46AM
Feb-24-25 05:14PM
Feb-21-25 08:00AM
Feb-13-25 05:41PM
Feb-12-25 07:42AM
Feb-03-25 06:30AM
Jan-27-25 06:30AM
Jan-17-25 05:31AM
Jan-16-25 07:30AM
Jan-13-25 06:30AM
Dec-19-24 06:38AM
Dec-11-24 07:02AM
Nov-27-24 07:09AM
07:30AM Loading…
Nov-20-24 07:30AM
Nov-19-24 07:02AM
Nov-14-24 04:40PM
03:32PM
Nov-09-24 02:14AM
02:05AM
Nov-08-24 11:15AM
06:45AM
Nov-07-24 06:30AM
Oct-28-24 06:30AM
Oct-22-24 07:02AM
Oct-17-24 07:30AM
Oct-16-24 03:03PM
Oct-10-24 07:00AM
Oct-09-24 05:35PM
06:30AM
Oct-02-24 06:30AM
Sep-24-24 07:30AM
Sep-09-24 06:30AM
Sep-05-24 07:00AM
Sep-03-24 07:30AM
Aug-28-24 06:30AM
Aug-26-24 07:02AM
Aug-08-24 10:49PM
05:30PM
06:45AM
06:27AM
Aug-05-24 06:30AM
Aug-02-24 03:22PM
Jul-31-24 09:15PM
04:15PM
Jul-29-24 07:02AM
Jul-25-24 06:30AM
Jul-11-24 08:45AM
Jul-06-24 06:39AM
Jun-24-24 09:40AM
06:40AM
Jun-21-24 07:00AM
Jun-20-24 08:23AM
06:30AM
Jun-14-24 07:15AM
Jun-05-24 09:25AM
May-31-24 08:36AM
May-29-24 07:15AM
May-28-24 07:02AM
May-24-24 08:10AM
May-20-24 07:00AM
May-15-24 07:30AM
06:30AM
03:02AM
01:12AM
May-14-24 11:53AM
08:00AM
06:43AM
May-10-24 04:05PM
07:45AM
May-08-24 06:00AM
May-03-24 07:30AM
May-02-24 07:15AM
Apr-29-24 08:30AM
06:45AM
Apr-28-24 11:59AM
Apr-26-24 12:35PM
09:05AM
06:30AM
Apr-19-24 07:13AM
Apr-16-24 10:53PM
Apr-12-24 07:30AM
Apr-10-24 07:02AM
Apr-08-24 12:13PM
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fernandes PrabhavathiDirectorNov 26 '24Buy0.9110,0009,09510,000Dec 02 04:15 PM
Castillo KirstenDirectorNov 22 '24Buy0.9125,00022,84875,000Nov 26 04:50 PM
RAMESH KUMARDirectorAug 16 '24Proposed Sale1.25116,705145,905Aug 16 04:16 PM